In addition, in T2DM patients with CKD, the use of finerenone (added to angiotensin-converting enzyme inhibitors (ACE-i) or angiotensin type II receptor blockers (ARBs), when residual albuminuria is present) is recommended to reduce the risk of cardiovascular disease and renal failure [28]. This evidence concerns the gene ACE and chronic kidney disease.